Evidence map›Paper›PMID 35578667›Full record

ArticleJournal of immunology research2022

A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.

Xin Zhang, Xingda Zhang, Guozheng Li, Yi Hao, Lei Liu, Lei Zhang, Yihai Chen, Jiale Wu, Xinheng Wang, Shuai Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xin ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Xingda ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Guozheng LiDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Yi HaoDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Lei LiuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Lei ZhangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Yihai ChenDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Jiale WuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Xinheng WangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Shuai YangDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Shouping XuDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China.ORCID https://orcid.org/0000-0001-6154-3381
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BRCA) is one of the leading causes of death among women worldwide, and drug resistance often leads to a poor prognosis. Necroptosis is a type of programmed cell death (PCD) and exhibits regulatory effects on tumor progression, but few studies have focused on the relationships between necroptosis-associated lncRNAs and BRCA. In this study, we established a signature basis of 7 necroptosis-related lncRNAs associated with prognosis and divided BRCA patients into high- and low-risk groups. Kaplan-Meier curves all showed an adverse prognosis for patients in the high-risk group. Cox assays confirmed that risk score was an independent prognostic factor for BRCA patients. The receiver operating characteristic (ROC) curve proved the predictive accuracy of the signature and the area under the curve (AUC) values of the risk score reached 0.722. The nomogram relatively accurately predicted the prognosis of the patients. GSEA analysis suggested that the related signaling pathways and biological processes enriched in the high- and low-risk groups may influence the tumor microenvironment (TME) of BRCA. ssGSEA showed the difference in immune cell infiltration, immune pathway activation, and immune checkpoint expression between the two risk groups, with the low-risk group more suitable for immunotherapy. According to the significant difference in IC50 between risk groups, patients can be guided for an individualized treatment plan. Overall, the authors established a prognostic signature consisting of 7 necroptosis-associated lncRNAs that can independently predict the clinical outcome of BRCA patients. The difference in the tumor immune microenvironment between the low- and high-risk populations may be the reason for the resistance to immunotherapy in some patients.

Indexed as

Breast NeoplasmsRNA, Long NoncodingBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNecroptosisPrognosisTumor MicroenvironmentBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID35578667
PMCPMC9107037
OpenAlexW4229074909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.